November 19, 2024

Can Fluid Restriction Stop MDMA Hyponatremia?

A 433% oxytocin increase—not vasopressin—correlated with MDMA-induced hyponatremia, with fluid restriction preventing all cases in a controlled setting.

Conexiant

November 19, 2024

Can High Dose Buprenorphine Improve Fentanyl OUD Outcomes?

Conexiant

November 13, 2024

Baltimore Secures $266M in Opioid Case

Reuters

November 13, 2024

Methadone, Buprenorphine Equal in New Guidelines

Meta-analyses showed both methadone and buprenorphine cut mortality risk in half compared to no treatment, marking a significant shift in Canadian guidelines that now recommend them as equal first-line options for opioid use disorder.

Conexiant

November 13, 2024

GLP-1s Show Promise for Alcohol Use Disorder

New data from 227,866 patients shows semaglutide associated with 36% reduced risk of alcohol-related hospitalizations versus traditional AUD medications' modest 2% reduction.

Conexiant

November 08, 2024

Adolescent Cannabis Use Associated with Psychosis Symptoms

Adolescent cannabis users show increased psychosis symptoms even before use begins, underscoring shared vulnerabilities and self-medication factors in psychosis risk.

Conexiant

November 06, 2024

Depression Risk Higher in Unmarried Adults

Among highly educated men in Western nations, being unmarried carried nearly double the risk of depression compared to married counterparts.

Conexiant

November 05, 2024

Psychosis Mortality Risk 2.6x After Sanctions

Psychosis patients face up to 2.6 times higher mortality risk after prison release, with overdose and suicide leading the causes—highlighting critical gaps in post-release care.

Conexiant

November 04, 2024

FTC Finalizes "Click-to-Cancel" Rule

FTC finalizes rule requiring subscription-based businesses to provide cancellation processes as simple as enrollment methods, effective 180 days after Federal Register publication.

Conexiant